STOCKS TELEGRAPH

Tag: SNOA stock

  • Sonoma (SNOA) Boosts Market Presence With UK Regulatory Success

    Sonoma (SNOA) Boosts Market Presence With UK Regulatory Success

    Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) experienced a sharp increase after a significant regulatory victory in the UK. SNOA stock was up 63.94% at $3.82 as of the most recent market check. Following the company’s news that its range of acne treatments based on hypochlorous acid had been successfully registered with the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), investor confidence skyrocketed.

    Strategic Retail Launch in Europe

    In the UK, a large health and beauty store will sell the approved products—an acne toner and a balancing serum—under its own name. More than 1,200 retailers nationwide are now scheduled to carry these products. This action represents a significant turning point in Sonoma Pharmaceuticals’ larger European distribution plan and their first significant foray into the UK consumer skincare sector.

    Dermatological Care Innovation

    With its all-natural hypochlorous acid and Sonoma’s exclusive Microcyn® technology, the acne product range provides a mild yet efficient substitute for conventional treatments like benzoyl peroxide and alcohol-based formulations. The company’s dedication to using safe, non-toxic chemicals is in line with the growing demand from customers for skincare products that are safer.

    Broadening Regulatory Footprint in the UK

    This most recent milestone comes after Sonoma’s production facilities and five of its medical goods—including skin exfoliants, hydrogel for wound care, scar management products, and wound irrigation solutions—were previously registered by the MHRA. These approvals emphasize the efficacy and safety of SNOA’s formulations, supported by clinical evidence suggesting that hypochlorous acid may successfully manage small skin lesions and irritations without hurting healthy tissue.

    Positioned for European Growth

    Sonoma Pharmaceuticals is well-positioned to increase its presence in the UK and larger European markets thanks to these regulatory achievements. The company views the UK as an important market for its dermatological and wound care products. These latest registrations’ success demonstrates SNOA’s dedication to international healthcare innovation and its potential for significant regional market expansion.

  • Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals (SNOA) Gains In Pre-Hour Trading

    Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares were rising 11.90% to $3.95 as of this morning’s last pre-market check. SNOA has made a number of encouraging announcements in the last week, which have led to this notable increase in stock value.

    New MHRA Registrations Signal the UK Market’s Growth

    The Medicines & Healthcare medicines Regulatory Agency (MHRA) recently granted Sonoma Pharmaceuticals permission to register its production facility and five important medicines in the UK. The recently authorized goods include a skin exfoliator, wound hydrogel, a variety of scar management solutions, and a wound irrigation solution based on hypochlorous acid.

    With this registration, Sonoma will be able to reach a wider audience and increase its market share in the UK by introducing its cutting-edge Microcyn-based products. The business was excited about the prospects for expansion this clearance offers in the dermatology and wound care industries.

    Adopting EU Medical Device Regulations with Success

    Sonoma Pharmaceuticals has accomplished a significant regulatory milestone in Europe in addition to registering in the UK. Four of the company’s products were successfully converted to conform to the Medical Device Regulation (MDR) of the European Union. These consist of Pediacyn for atopic dermatitis, Microdacyn60 Wound Care, Microdacyn60 Hydrogel, and the scar gel Epicyn.

    Strict requirements for the performance and safety of medical devices are mandated by the MDR, which took the place of the old Medical Device Directive in 2017. A noteworthy accomplishment is Sonoma’s early adherence to these new rules, which guarantees that its goods will satisfy all safety and legal criteria before the December 2028 date.

    Evidence of Regulatory Readiness and Product Safety

    Sonoma’s dedication to product safety and regulatory vigilance is demonstrated by the successful registration and classification of its products as Class IIb medical devices in Europe. The company’s solid clinical data and capacity to adjust to changing international requirements are clearly demonstrated by the shift to MDR compliance.

  • Sonoma (SNOA) Stock Rallies After Reverse-Split Trading Begins

    Sonoma (SNOA) Stock Rallies After Reverse-Split Trading Begins

    The value Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares are increasing significantly today, indicating that the market has responded favorably to the company’s switch to a reverse-split. SNOA stock surged 9.66% to $3.49 as of the most recent check.

    Specifics of the Reverse Stock Split

    Previously this week, Sonoma Pharmaceuticals announced that it will reverse its stock split one-for-20. The split was planned to take effect on August 29, 2024, at 5:00 PM EDT. The company’s shareholders approved the reverse split during the annual meetings on August 14–23, 2024, which led to this decision.

    The Board of Directors authorized the split and set the ratio on August 23, 2024. In order to preserve Sonoma’s listing status on the Nasdaq Capital Market, a calculated strategic maneuver was made with the reverse stock split. Sonoma hopes to increase investor interest, boost stakeholder confidence, and open up new business growth options by keeping its Nasdaq listing.

    Every twenty shares of Sonoma’s common stock will convert into one new share, without altering the par value per share. Consequently, the total number of shares will reduce from approximately 20 million to around one million.

    Operational Developments

    Operationally, Sonoma Pharmaceuticals has expanded the claims for its Nanocyn Disinfectant and Sanitizer after the Australian Therapeutic Goods Administration (TGA) granted an extension. Utilizing Sonoma’s proprietary Microcyn technology, Nanocyn is manufactured for MicroSafe and has received additional approvals for its ability to effectively combat Clostridium difficile (C. diff.) and Candida auris (C. auris) in less than ten minutes.

    Nanocyn has previously been approved by the Australian Register of Therapeutic Goods for use against a variety of germs, viruses, influenza A, and SARS-CoV-2. Nanocyn is already recognized by the Environmental Protection Agency (EPA) of the United States as a disinfectant that effectively fights diseases such as MRSA, Salmonella, mpox, SARS-CoV-2, and others.

    Strategic Impact

    By tackling a variety of dangerous pathogens, these additional TGA approvals strengthen Sonoma Pharmaceuticals’ leadership in broad-use disinfection technology and reaffirm its dedication to strict safety regulations.

  • Sonoma Pharmaceuticals Inc. (SNOA) stock Bullish on News of Partner Network Expansion

    On January 20, Sonoma Pharmaceuticals Inc. (SNOA) announced its partner network expansion for oral and dental products in the U.S. and China. Following the announcement, the stock became bullish in the after-hours session.

    The stock was gloomy in regular trading as it lost 2.30% at its closing price of $4.25 on Thursday. Consequent to the news, SNOA reversed to add 8.00% in the after-hours. Hence, it was trading a $4.59 per share at an after-hours volume of 259.52K shares.

    Sonoma Pharmaceuticals Inc. has a market capitalization of $13.47 million. Currently, the company has 3.1 million shares outstanding in the market.

    SNOA’s Partner Network Expansion

    Firstly, the company has expanded its U.S. dental care partner network by adding Salus Medical as a distribution partner. Furthermore, the company has entered into a non-exclusive agreement with Salus Medical for the distribution of Endocyn® root canal irrigant. Additionally, with SNOA’s Microcyn® RX and Regenacyn® Plus products, Salus Medical would widen its dermatology offerings. Salus Medical will have non-exclusive rights for the distribution of Microcyn® products.

    Salus Medical is a Phoenix, Arizona-based national wholesale distributor.

    Secondly, the company has also entered into a partnership deal with Anlicare International. Thus, Expanding its oral and dental care line to China. On January 18, SNOA and Anlicare agreed for working on the completion of required regulatory work for obtaining Microcyn®-based products distribution licenses in China. As per the agreement, Anlicare will be responsible for the regulatory costs. In return, the company will grant exclusive distribution rights to Anlicare for oral and dental care products in China.

    Anlicare International brings and commercializes innovative medical devices and consumables to the Chinese market.

    Recent Participation

    Recently, the company participated in the H.C. Wainwright BioConnect Virtual Healthcare Conference. The conference took place from January 10 to January 13, 2022. SMOA’s CEO, Amy Trombly, and CFO, Jerry Dvonch presented an overview of the company’s business at the conference.

    SMOA’s Q2 FY2022 Financials

    On November 15, the company announced its financial results for the second quarter of fiscal 2022, which ended on September 30, 2021.

    In the second fiscal quarter of 2022, the revenues were $3,744,000 against $5,769,000 in the year-ago quarter. Hence, showing a decrease of 35% year over year.

    Moreover, SMOA suffered a net loss of $95,000 from continuing operations in Q2 of fiscal 2022. Comparatively, the company had a net income of $151,000 in the same period last year.

  • Sonoma Pharmaceuticals, Inc. (SNOA) Stock Drops Significantly Despite Promising Financial Reports for Fiscal Q4 2021

    Sonoma Pharmaceuticals, Inc. (SNOA) stock prices were down 18.88% some time after market trading commenced on July 15th, 2021, bringing the price per share down to USD$6.23 early on in the trading day.

    Partnership with EMC Pharma

    March 26th, 2021 saw the company report having entered into a new partnership with EMC Pharma in light of it having gained exclusive rights for the U.S commercialization of prescription dermatology and prescription eye care products. The pharmaceutical company was also granted non-exclusive rights to sell their wound care products into government channels. The initial term of the agreement is subject to minimum purchases and is set for five years, with the option to renew.

    Network of Partnerships

    September 2020 saw the company launch two new products, Nasocyn Nasal Care and Oracyn Oral Care in collaboration with its partner, Te Arai Biofarma Ltd. December 2020 saw the company partner up with Gabriel Science, LLC in order to penetrate the dental markets in the U.S with their HOCI product. January 2021 saw the company receive clearances in Thailand, after which the sales of Dermodacyn disinfectant commenced in Hong Kong and Thailand, through its partner, VetSynova Co. Ltd.

    Total Revenues

    Total Revenues for the quarter ended March 31st, 2021 came in at USD$2.2 million, down by USD$2.1 million as compared to the same time period of the prior year. The 50% reduction was largely driven by the USD$1.6 million decline in the U.S, which, in turn, was motivated by the decline of the company’s dermatology business. The dermatology business has since been partnered with EMC Pharma, LLC. Further compounding the year-over-year difference was USD$800,000 in revenue adjustments in relation to the overestimation of revenue in the prior-year quarter, having been determined using a look-back analysis.

    Invekra Contract

    As a result of the Invekra contract having concluded in October of 2020 resulted in a USD$0.7 million reduction in revenues generated from Latin America sales, further contributing to the yearly difference in total revenue. As per the contract, SNOA the company manufactured at low margins for Invekra. Since the conclusion of the contract, manufacturing has continued at reduced quantities but higher margins.

    Future Outlook for SNOA

    Armed with a network of partnerships secured over the past few quarters, SNOA is poised to capitalize on the chances afforded to it. The company is keen to continue its trajectory of success as it pushes for the consolidation and expansion of its market footprint around the globe. Current and potential investors are hopeful that management will be able to usher in sustained and significant increases in shareholder value.

  • Sonoma Pharmaceuticals Inc. (SNOA) stock rises during pre-market trading. Here’s to know why?

    Sonoma Pharmaceuticals Inc. (SNOA) stock surged by 8.47% at the last trading close whereas the SNOA rises by 26.78% in the pre-market trading after it announced their agreement with EMC Pharma, LLC. Sonoma Pharmaceuticals is a worldwide healthcare pioneer in the development and production of stabilized hypochlorous acid (HOCl) products for wound treatment, animal health, eye care, nasal care, oral care, disinfectant use, and dermatological conditions.

    What is happening?

    Sonoma announced that it has entered into a definitive agreement with EMC Pharma, LLC for the exclusive right to manage, market, and distribute Sonoma’s HOCl-based prescription dermatology and eye care products in the United States for a five-year period, with an option to extend. EMC Pharma will also have a non-exclusive contract with the government to manage, supply, and distribute such Microcyn-based wound care products. EMC Pharma is a national healthcare products and services firm that operates in FDA-approved prescription medication creation, pharmaceutical distribution, and effective pharmacy services.

    EMC will purchase all of the current inventory and pay a royalty and transfer rates for the first five years as part of the collaboration deal. To keep the distribution rights reserved, the parties agreed on certain minimum purchase conditions. The CEO of SNOA said that, through this agreement with EMC we are intending to increase our distributor network in order to enhance their approach for patients and consumers on national level and for this purpose EMC is the most appropriate platform due to its wide distribution network and experience in this business.

    Furthermore,

    Sonoma’s direct sale model was not really working in favor of SNOA therefore following this new agreement SNOA has reduced its sales force, working for the direct sale model in USA. The management of SNOA hopes that partnering with EMC would enable the company to cut costs while working with EMC to develop a profitable distribution model for its prescription drugs.

    Hence, this recent development in SNOA has caught the attention of investors which resulted in the rise of SNOA stock price. But the investors are still expected to be more careful before they make bet for a long-term.

  • Early Morning Vibes: 3 Upgraded & 4 Pre Market Hot Stocks Inside

    Early Morning Vibes: 3 Upgraded & 4 Pre Market Hot Stocks Inside

    On December 10, the American stock indexes finished trading in different directions. The S&P 500 Index dropped 0.13% to 3668 points, the Dow Jones lost 0.23% and the NASDAQ rose 0.54%. Investors could not determine the direction of movement and took a wait and see attitude. Note that small-cap stocks showed more pronounced positive dynamics: the Russel 2000 index rose 1.08%. The industrial sector was an outsider, shedding 0.93%. 

    Corporate updates 

    Starbucks (SBUX: 5%) management presented a positive outlook for the company over the next few years.

    Snap (SNAP: + 8.1%) and Twitter (TWTR: + 8.4%) have announced a service integration partnership. Tweets can be shared on the Snapchat platform.

    Adobe’s quarterly results (ADBE: -1.4%) were better than expected, but its stock corrected.

    Today, global stock exchanges are showing mostly negative dynamics. The focus of attention is the decision of the FDA expert panel, which recommended approval of the coronavirus vaccine developed by Pfizer and BioNTech. However, no official permission was issued for the use of this drug, although market participants were counting on this. The market now assumes that a positive decision will be made this weekend, and then within 24 hours the first 6.4 million doses will be shipped to different states. Waiting for a vaccine approval within three months was the main driver of market growth.

    Lack of further progress in negotiations on the US economic aid package, persisting tensions with China and COVID-19 incidence statistics are factors that reduce risk appetite in the short term. The alarming signal yesterday was the publication of data on applications for unemployment benefits. Their number unexpectedly increased to 853 thousand in a week, while the forecast was 725 thousand. Macro statistics were ignored by the market, however, in our opinion, it serves as a harbinger of a deterioration in the state of the economy in early 2021 due to quarantine restrictions reintroduced by some states.

    Economic Update

    The University of Michigan Preliminary Expectations and Consumer Sentiment Index for December will be released today. The consensus assumes an increase in the first indicator from 70.5 to 71.0, while the second decreases from 76.9 to 76.5 points. The Expectations Index should be boosted by consumer hopes for mass vaccinations. Before the pandemic, the sentiment index was at the level of 99-100, the pressure on it continues to be the absence of a new package of economic assistance measures and stabilization of the epidemiological situation.

    Top Upgrades & Downgrades

    Morgan Stanley turned bullish on Diamondback Energy Inc. (FANG), upgrading the stock to “Overweight” and assigning a $65.0 price target.

    CommScope Holding Company Inc. (COMM) has won the favor of JP Morgan’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $18.0.

    Cognizant Technology Solutions Corporation (CTSH) received an upgrade from analysts at JP Morgan, who also set their one-year price target on the stock to $93.0. They changed their rating on CTSH to Overweight from Neutral in a recently issued research note.

    Earlier Friday JP Morgan reduced its rating on Juniper Networks Inc. (JNPR) stock to Neutral from Overweight and assigned the price target to $25.0.

    JP Morgan analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Corning Incorporated (GLW) has been changed to Neutral from Overweight and the new price target is set at $39.0.

    Today Top Movers

    vTv Therapeutics Inc (VTVT) share price soared 184.47% at $6.23 in today’s pre-market session after the report that in compliance with the terms of the letter arrangement between the Firm and the Investor dated December 23, 2019, the company exercised the right to allow MacAndrews & Forbes Group LLC buy 625,000 shares of the Company’s Class A common stock at a per share price of $1.60.

    In trading session of premarket today, BioNTech SE (BNTX) share price went up 0.07% at $29.63 after the company and Pfizer reported the receipt FDA advisory committee vote in supporting potential first emergency use authorization for vaccine to combat COVID-19 in the U.S.

    Sonoma Pharmaceuticals Inc (SNOA) showing bullish trend in early morning on Friday, increasing 33.44% of its share price at $8.18 following an announcement of agreement with Crown Laboratories, Inc., to Launch Microcyn technology-based anti-Itch over-the-counter products.

    Zedge Inc (ZDGE) is going up 21.48% in premarket session on Friday after reporting first fiscal quarter revenue growth of 85% and record overall quarterly financial results.

    Latest Insider Activity

    Advanced Micro Devices Inc. (AMD) President & CEO Su Lisa T announced the sale of shares taking place on Dec 08 at $92.89 for some 150,000 shares. The total came to more than $13.93 million.

    Twitter Inc. (TWTR) Chief Financial Officer SEGAL NED D. sold on Dec 08 a total 634,970 shares at $47.93 on average. The insider’s sale generated proceeds of almost $0.34 million.

    Regulus Therapeutics Inc. (RGLS) 10% Owner Sonsini Peter W. declared the purchase of shares taking place on Dec 04 at $0.62 for some 4,398,602 shares. The transaction amount was around $2.74 million.

    Boxlight Corporation (BOXL) CHIEF EXECUTIVE OFFICER Pope Michael Ross bought on Dec 09 a total 287,942 shares at $1.65 on average. The purchase cost the insider an estimated $66,000.

    Earnings To Watch

    Top US earnings releases scheduled for today include Construction Partners Inc. (NASDAQ:ROAD). It will announce its Sep 2020 financial results. The company is expected to report earnings of $0.3 per share from revenues of $241.5M in the three-month period.

    Analysts expect Johnson Outdoors Inc. (NASDAQ:JOUT) to report a net income (adjusted) of $0.8 per share, when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Sep 2020 is predicted to come in at $125.44M.

  • Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares taking aerial root after this announcement

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares taking aerial root after this announcement

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares hiked 32.30%  to reach $8.11 in the pre-market session after the announcement that they have reached a license and supply agreement for exclusive rights to market and sell products in the United States for over-the-counter (OTC) dermatological products.

    Crown plans to sell Sonoma’s Microcyn technology dermal sprays and gels targeting itch and pain under Sarna, the #1 Dermatologist Recommended Anti-Itch Brand, with a unique variety of formulations to quickly relieve itch and skin irritations.

    The HOCl line of products from Sonoma is clinically proven to reduce burning, itching, and pain in patients suffering from different kinds of dermatoses, including radiation dermatitis and atopic dermatitis. Sonoma will continue to sell prescription drugs, while Crown will offer over-the-counter products.